Floatz logo

Idarubicin

Myeloid Sarcoma

M.D. Anderson Cancer CenterSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

23 Active assets in the Myeloid Sarcoma cohort.

Asset / SponsorPhaseRating
CYTARABINE
Kura Oncology, Inc.
Phase 3BB
Mitoxantrone
Ruijin Hospital
Phase 3BB
Daunorubicin
Kura Oncology, Inc.
Phase 3BB
ETOPOSIDE
St. Jude Children's Research Hospital
Phase 3BB
Venetoclax
Ruijin Hospital
Phase 2BB

View all 31 →

Same molecule, other indications

Idarubicin is also rated in:

acute promyelocytic leukemiaDormant
A
Indicative ·
81 / 100
View asset →
acute myeloid leukemia with 11q23 abnormalitiesDormant
BBB
Indicative ·
76 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →